The impact of storage conditions on compound stability and compound solubility has been debated intensely over the past 5 years. At Novartis, the authors decided to opt for a storage concept that can be considered controversial because they are using a DMSO/water (90/10) mixture as standard solvent. To assess the effect of water in DMSO stocks on compound stability, the authors monitored the purity of a subset of 1404 compounds from ongoing medicinal chemistry projects over several months. The study demonstrated that 85% of the compounds were stable in wet DMSO over a 2-year period at 4 °C. This result validates the storage concept developed at Novartis as a pragmatic approach that takes advantage of the benefits of DMSO/water mixtures while mediating the disadvantages. In addition, the authors describe how purity data collected over the course of the chemical validation of high-throughput screening actives are used to improve the analytical quality of the Novartis screening deck. (Journal of Biomolecular Screening 2008:999-1006 
INTRODUCTION
I T IS LARGELY RECOGNIZED THAT THE SUCCESS of a high-throughput screening (HTS) campaign depends on the quality of the biology of a screen and on the quality of the screening collection. The quality of the screening collection can be described in terms of the diversity and size of the collection and the physical integrity of the compounds. In the late 1990s, most of the pharmaceutical companies focused their attention more on collection growth than on collection integrity. In this respect, compound management processes evolved considerably, and there has been increased activity in this field, resulting in the publication of several papers and conference reports over the past 5 years.
Three publications from 2006 can serve to assess the relevance of investigating stability issues in the context of storage of large compound libraries. Ilouga et al. 1 investigated the purity of a set of 778 highly diverse compounds for 6 months. Conditions selected for the stability study were -20 °C under argon, -20 °C under ambient atmosphere, and 15 °C under argon. The experimental data revealed that storage at 15 °C leads to a fast reduction of compound amount, even under argon compared with -20 °C data, and that after 6 months there was no significant difference in the mean degradation of compounds between storage with or without inert gas. The authors also established a statistical projection of compound integrity over 4 years for all 3 storage conditions and concluded that storage under inert gas atmosphere is relevant for long-term storage of more than 12 months. Bowes et al. 2 reported results obtained for 2 different sets of compounds, 470 discrete compounds, and 1917 combinatorial compounds, stored in 2 different formats, 10-mM DMSO stocks at 4 °C and lyophilized dry films, over 3 years. The study showed that the discrete collection had greater purity, with 63% of compounds having >80% purity after the 3-year storage period. In contrast, 57% of the combinatorial compounds had >60% purity after the same period. Thereby, the authors draw attention to purity discrepancies related to compound sources. Both studies were performed on a subset of the compound collection because cost associated with the testing of the entire collection would be prohibitive. These investigations help library managers to establish mid-term strategies for a progressive enhancement of the quality of their collections. In a different strategy, Lane et al. 3 described the project implemented at GlaxoSmithKline that achieved a radical cleanup of the 1.4 million repository compounds by analyzing the entire collection over 18 months. Overall, 61% of compounds were found to pass the first selection criterion (UV purity >80%), and this pass rate was found to be consistent for both heritage collections, although their composition and storage conditions were fairly different.
A common approach in compound storage facilities is to store dry DMSO samples at temperatures ranging from -20 °C to 4 °C and at low relative humidity. [4] [5] [6] Most of the industry invested considerably in infrastructure minimizing moisture during solution production/reformatting and solution storage. However, despite this effort, it is extremely difficult to maintain the water content of DMSO below 0.5 to 1%. 7 An alternative concept was developed at the Novartis Compound Archive in the late 1990s. We and others decided to use the benefits of storing 2-mM stocks in a DMSO/water (90/10) mixture. At storage conditions of 4 °C and 20% relative humidity, further water uptake will be very slow, 8 and with the addition of 10% water, the freezing point of DMSO drops from 18 °C to below 4 °C. This freezing point depression allows one to avoid repeated freeze/thaw cycles that could affect unfavorably the solubility of some compounds. By combining these advantages-no freeze/thaw cycles, low stock concentration, and minimal water uptake-we believe that solubility issues are minimized and less precipitation issues are observed because the solution collection concentration is switched from 10 mM (100%) to 2 mM (90% DMSO). At the same time, retrieval of samples will be rapid because no melting step is required. Because water-labile compounds are largely removed from the screening collection using substructure filters, a regular 6-year resolubilization cycle is considered adequate to maintain a high analytical quality of compounds. 9 The use of wet DMSO as standard solvent for the preparation of screening solutions has been intensely debated because the deleterious effect of water on compound stability is considered a serious concern. For instance, Cheng et al. 10 reported an experiment in which 644 compounds were selected from the Abbot collection and subjected to different storage conditions. The effect of temperature, oxygen, water, freeze/thaw cycles, and material container was evaluated. In an accelerated 40 °C study comparing compound stability in dry DMSO samples and wet DMSO samples (5% water in DMSO) over 26 weeks, the data indicated that water had a negative impact on the quality of the 10-mM DMSO stocks. After 3 weeks of storage at 40°C , 91% of wet samples were found with 80% or more of the initial concentration remaining versus 96% for the dry samples. After 26 weeks of storage, the percentage decreased to 63% for the wet samples versus 66% for the dry samples.
In this contribution, we disclose a study we undertook to assess the Novartis storage concept. We started to assess the purity of 1404 compounds stored in a DMSO/water mixture (90/10) over 2 years. Representative compounds out of ongoing medicinal chemistry programs were used as a test set. As historical collections often are biased in their properties, compounds from a broad range of lead optimization efforts were considered a good representation of current thinking in medicinal chemistry.
In a second part, we describe how the analytical data collected at different stages of the compound workflow are used in the life cycle management of the Novartis compound library.
Several quality control (QC) processes are set at different stages of the compound workflow to check the quality of screening samples over this life cycle. Although we perform spot checking of purchased libraries and random selections, our main effort is currently dedicated to validate purity and identity of HTS hits. Previously, the analytical validation of screening hits was done sequentially: after the biological validation step, a list of confirmed samples was submitted to chemical validation. With the automation of the chemical validation, primary hit lists can be forwarded to chemical validation and to biological validation in parallel, speeding up the screening process. A follow-up process on powder samples used for the production of screening solutions was also recently set up to correct data for high-quality samples that could not be identified according to the data recorded in the chemistry database.
MATERIALS AND METHODS

Stability study under Solution Archive storage conditions
In total, 1404 stock solutions (10 mM, 100% DMSO) were prepared manually and carefully checked for complete solubilization of the compounds by visual inspection. Stocks were then diluted to 2-mM stocks (DMSO/water [90/10]) and transferred into 384-deep-well plates that were sealed and loaded into the Solution Archive (SOLAR, 4 °C and 20% relative humidity in the dark). Two copies of deep-well plates are typically loaded into SOLAR for 3 years. The first copy (copy A) will be used in the first 18 months and will be unloaded after this period. The system will then switch automatically to the second copy (copy B), which is untouched and sealed until that point. Copy B will then be used as a source plate for the production of primary screening plates for a further 18 months.
Six time points were set within a period of 24 months, and the study time currently has been extended to an overall period of 3 years, which corresponds to the lifetime of a library plate in our life cycle management.
The first measurement was performed after loading the newly created library in the Solution Archive, a maximum of 2 weeks after solution production. The last measurement, which was conducted 24 months after creation of the plates, was performed on solutions taken out of copy B. Relative purity was determined by liquid chromatography/mass spectrometry (LC/MS) after 3, 8, 11, 18, and 24 months of storage. Then, 5-μL aliquots of 2-mM stocks were transferred from source plates into Matrix polypropylene plates and were diluted just prior to injection.
LC/MS system: hardware and software
Parameters used for the 2-year stability study. The study was run with a method created on a standard LC/MS system (LC Series 1100, Agilent, Waldbronn, Germany). The chromatographic Engeloch et al.
separation was achieved with 3.0-μm particles. Atlantis dC18 columns from Waters with a dimension of 2.1 × 20 mm were held at room temperature. The mobile phase consisted of A: 95% water/5% acetonitrile + 0.05% trifluoroacetic acid and B: acetonitrile + 0.035% trifluoroacetic acid + 30 mM ammonium acetate and was degassed online. The analytical separation was performed at a flow rate of 1.0 mL/min and a linear gradient from 5% to 100% B in 1.3 min, kept until 1.5 min at 100% B, returned to initial conditions at 1.9 min, and reequilibrated until 4.0 min. A CTC PAL autosampler with dilutor was used for online dilution and 3-times mixing of the 5-μL DMSO sample solution with 15 μL acetonitrile/water 1/1 prior to injection of a 5-μL sample. UV detection was achieved with a diode array detector (DAD SL, Agilent) recording at fixed wavelengths of 214 and 254 nm. The LC system was connected to a quadrupole mass spectrometer (MSD SL, Agilent) equipped with an electrospray ionization source (ESI-source, Agilent). The mass spectrometer was operated in full-scan acquisition mode ranging from 100 to 1200 amu in 1.3 s. Fragmentor voltage was set at 35 V, capillary voltage at 4000 V, drying gas temperature at 350°C, nebulizer pressure at 60 psig, and drying gas flow at 13 L/min.
The LC/MS system was equipped with 2 workstations (HP Compaq, P4, 3.4 GHz, 2 GB RAM), one for system control and the second workstation for data processing. Automated data processing was achieved with a custom-tailored application written by INTEG Software Integration GmbH (Remchingen, Germany). The highly customized software solution offered maximum automation and unattended performance of the LC/MS systems. Sample list generation was automated by the INTEG software and required simply scanning the barcode of the 384-well plate samples positioned in the autosampler. The hyper-sequence approach allowed queuing of multiple sequences of samples ranging from single-sample batches of multiwell plates. Peak integration for purity determination was performed by ChemStation (CS B.03.01 [313] Agilent) and based on the signal at UV 214 nm. INTEG software performed alignment-extracted ion chromatograms in positive and negative modes found for a predefined adduct list. The MS elution time was then obtained by matching these extracted ion chromatograms. The purity was determined from the corresponding UV peak in the 214-nm trace. Results were categorized according to identity, based on mass spectrometry data and purity, based on the UV 214 chromatogram. Finally, the sample was flagged according to identity and purity results (Fig. 1) .
The identity flag indicates whether the expected molecular weight was found. The purity flag then indicates the level of relative purity as determined in the UV 214 trace. For better understanding of the analytical process of compound validation by LC/MS, the result category "NOT FOUND" was further divided into several subcategories as shown in Figure 1 .
The category "NOT FOUND Empty Well" was assigned to an empty well and was triggered by the absence of the characteristic DMSO peak at the solvent front in the chromatogram. Different reasons can lead to this scenario, ranging from technical issues during sample handling to faulty injection on the analytical system. Category "NOT FOUND DMSO Only" was triggered by a UV 214 chromatogram that contained Only the DMSO peak at the solvent front. A compound coeluting with DMSO or a compound with no absorption at UV 214 can cause this effect. Other subcategories of NOT FOUND represented samples in which the expected molecular weight was not confirmed by mass spectrometry and the sample was either pure (NOT FOUND UV Pure) or a mixture (NOT FOUND UV Mixture). Failed confirmation of target molecular weight by mass spectrometry can be due to a different structure than expected, as well as poor ionization of the compound or quantitative fragmentation. The last category (NOT FOUND No Structure, 5) contained all compounds without known chemical structure. Thus, identity flag "FOUND" can be combined with 4 different purity flags, and "NOT FOUND" was accompanied with 1 of 5 different subcategories, as shown in Figure 1 .
RESULTS AND DISCUSSION
Two-year stability study
The study was started to monitor the chemical stability under our Solution Archive (SOLAR) conditions (solvent: Compounds from a broad range of ongoing medicinal chemistry programs were chosen as test compounds that optimally represent a subset of diverse compounds with drug-like properties. An initial set of more than 1500 compounds was subjected to established substructure filters 8 that are routinely applied to our library selection process. After removal of duplicates, a final selection of 1404 compounds was then defined as the test set.
To test how well the selected 1404 compounds represent the entire compound collection, we compared the diversity of this set with the diversity of the collection by 2 methods. First, the distribution of molecular properties (molecular weight, number of H-bond donors and acceptors, number of rotatable bonds, cLogP, and PSA) of this set was compared with the distribution of the same properties in the whole collection, and no significant differences were found. In the second test, the selected compounds were mapped to a 2D Kohonen map. In this method, each molecule was coded by a descriptor vector that encodes the distribution of the distances between pharmacophoric features of the molecule (radial codes) in the energy-optimized 3D conformation. The descriptor vectors were then mapped onto a selforganizing neural network (Kohonen map). The method is described in greater detail in a 2006 publication. 11 We first trained the 20 × 20 neuron map with a representative subset of the compound collection (12,000 compounds) and then mapped the 1404 compounds from the study set onto it. The selected 1404 compounds did not form any clusters on the map, suggesting that the selected set has a high degree of diversity.
The purity was assessed by LC/MS/UV at regular time points over 24 months (Fig. 2) .
Overall, the study revealed that most compounds were remarkably stable in wet DMSO. After 18 months of storage (period when measurements were performed on the same copy), 85% of compounds were still found with a relative UV purity of higher than 85% (called "pure" in the remainder of the text). The biggest loss in purity can be observed in the first 3 months. At the beginning of the study, 91% of compounds were pure, but after 3 months, this percentage had decreased to 88%. In the ensuing 21 months of the study, the percentage decrease for the "pure" category was less pronounced-namely, 1% per semester.
Purity profiles over 18 months were analyzed and categorized as follows ( Fig. 3) :
Categories A-C: 1227 compounds were found to be stable in wet DMSO (purity above 80% for the 5 measurements). Category D: 49 compounds showed low but similar purity as in the beginning of the study. Category E: 63 compounds showed gradual degradation. Category F: 65 compounds were not detected by LC/MS. Artifacts, such as those illustrated in Figure 3C , were corrected according to the trend given by the rest of the measured points.
The data variability was assessed by analyzing the samples in duplicate at the 18-month time point (Fig. 4) . We identified 20 of the 1404 samples (1.4%) that deviated more than 5% from the ideal correlation. Outliers can be divided into 3 categories:
Samples showing weak UV signals. In this case, the peak integration can easily differ from run to run, and this will affect in first line the purity result. Samples generating weak MS signals just below or above the noise threshold will not always be detected. Isomer mixtures whose UV peaks are overlapping can be integrated either as 1 peak or as 2 distinct peaks depending on the separation achieved during the LC run.
These borderline categories are problematic for any kind of automated LC/MS data analysis and cannot be avoided. The only way to handle them properly is to flag them as an equivocal result. The flagging of samples where weak signals were monitored, for example, was automated, and the uncertainty regarding the identity or the purity of the sample was then retranscribed in the identity flag (e.g., FOUND_ weak UV or NOT FOUND_ weak MS).
For those samples that were impure from the beginning of the study (profile D), we determined the purity of the powder sample that had been used to prepare the screening solution. Solutions were freshly prepared and analyzed immediately. Of the 49 samples, 29 compounds were available as powders. For 72% of powder samples, similar purity range (within ±20%) was found as for the screening solution. Only 18% of powder samples had a higher purity than the screening solution. Unexpectedly, 4 powder samples (10%) even showed a lower relative purity than the screening solution. In each of the 4 cases, the UV trace for the powder sample revealed the presence of at least 3 side products that showed slightly different integration data compared with the data obtained for the corresponding screening solution. In the case of very unstable and complex mixtures, accumulated data variation can cause unexpected discrepancies.
For those compounds that had proven to be unstable in wet DMSO (profiles D, E), we attempted to determine the responsible structural element. Clustering the unstable compounds, 10 scaffolds could be identified. From the ion peaks of the mass spectra, it was possible to postulate a probable pathway of degradation for 4 series. We observed elimination reactions such as loss of carbon monoxide, cyclizations, and hydrolysis. However, not all compounds that shared the identified scaffold were instable, pointing to other factors that determine compound stability (structural characteristics, salt form, presence of impurities/reagents).
Compounds belonging to the category E (4.5% of the complete compound set) are currently used in a secondary study to evaluate the real impact of water on the degradation process.
During the 18 months of the study, the source plates had been repeatedly brought from cold storage to room temperature and accessed to take samples. The source plates were then reloaded to the store, with the broken (pierced) seal covered with a lid. We therefore wanted to determine if the repeated warming to room temperature and exposure to oxygen had any detrimental effect on compound stability. A second set of plates (copy B) that had been stored with an intact seal under the same conditions was analyzed after 24 months. The purity of the samples was found to be similar to the results obtained for the corresponding A copies after 18 months. This suggests that the storage conditions of copy A plates, with a pierced seal and a lid, did not lead to substantial additional degradation. The addition of 10% water to DMSO achieved stable conditions under which the integrity of pierced plates could not be distinguished from sealed plates.
Quality of the study set versus quality of the active screening deck
The goal of this study was to test the stability of a highquality compound set under the storage conditions developed at Novartis-namely, storage in a DMSO/water (90/10) mixture at 4 °C and at 20% relative humidity. Often, such studies are hampered by a lack of knowledge about the purity of the drypowder sample that was used to generate the screening solution. To avoid this difficulty, we used a selection of compounds out of ongoing medicinal chemistry programs and obtained the first purity measurement shortly after preparing the solution. After 2 years, only 6% of compounds had a lower purity than at the beginning of the study; 85% of samples were still >85% pure by LC/MS/UV. This good result can be explained by the specificity of the compound source but also by the fact that a very stringent set of substructure filters was used to select the compounds entering the Solution Archive. Many efforts were invested in refining our set of filters, and this affects a lot of the quality of the samples entering the Solution Archive as well as the quality of samples delivered to the screening groups (significant increase of hits validated by LC/MS over the past 5 years). The quality of this study set does of course not represent the quality of the current screening deck. The Novartis compound collection is, like most other large pharma collections, a heterogeneous collection with compounds of different quality Fig. 5) . Because this data set represents more than 10% of the screening collection, it can be considered representative and should allow extrapolation of the overall purity of the screening deck. As expected, a lower purity was found for the HTS actives than for the study set. Only 65% of compounds were found to have a purity higher than 85%, and an additional 15% had purities of 50% to 85%. Low-quality solutions with purities below 50% amounted to 10%, and for a further 10% of samples, we did not observe the expected mass in the MS. These numbers are consistent with data published on the quality of large compound collections. Among others, Lane et al. 3 concluded that these numbers are typical for large, historical compound collections assembled over the same period of time. It is noteworthy, though (and corroborates the result of our study), that the adoption of this pragmatic concept that put no emphasis on storage in dry DMSO did not result in a solution collection of detectable lower quality.
These results are not only used to inform decisions on future compound management investments. The data are also used to continuously improve the analytical quality of the library. For instance, data suggested for a particular compound source that only 50% of the compounds were found with a purity higher than 85%, and for 25% of the samples, the expected mass could not be detected in the MS. This observation triggered the start of a full QC process on solutions from this compound source and the systematic use of the analytical data in the compound reselection process for new screening library production.
Compounds showing a purity greater than 50% are reselected for solution production. Low-quality stocks (purity lower than 50%), either from impure solid material or from degradation under the solution storage conditions, are deemed unsuitable for HTS and are thus excluded from the library (Fig. 6) .
Unidentified samples of high purity (UV purity higher than 85%) are not excluded and are reintroduced in new libraries. Because these compounds are pure, they have the potential to yield interesting lead structures. The structure elucidation process will be initiated if they appear at a later stage on a hit list. Samples flagged as "NOT FOUND_UV PURE" after the chemical validation are systematically subjected to a follow-up process (Fig. 7) .
The powder sample that was used to prepare the screening solution is submitted immediately after new solution preparation to a second LC/MS analysis. If the mass retrieved for the powder sample matches with the mass retrieved for the screening solution, the full structure elucidation process is started. This triage step allows us to focus analytical efforts on highpurity samples that can be corrected without ambiguity. All solid batches stored in our archives are checked for consistency before correcting definitively the structure in the database.
Samples without structure information and "NOT FOUND UV Mixture" samples are definitively excluded from the compound selection. A follow-up process for the category "NOT FOUND DMSO Only" is currently under evaluation. Implementation of additional universal detectors, such as evaporative light scattering (ELSD) or charged aerosol detection (CAD), could add additional information for this category.
The challenge of establishing follow-up processes is to retrieve enough information to be able to decide on the exclusion of unidentified compounds without investing unreasonable amounts of analytical resources.
We developed a life cycle management that allows us to store our screening collection in wet DMSO at a high purity level for 2 periods of 3 years. We also opted for a progressive enhancement of the compound collection by focusing first on our efforts in removing low-quality stocks from libraries identified to be problematic. The major challenge in the coming years will be to establish a full QC process for all solutions entering the Solution Archive to be able to check sample integrity requirements before their inclusion into the screening deck. Correction of structure data and removal of low-quality samples should occur in an earlier stage. After clean up based on production checks (availability, exclusion flags, structure information) MAIN 
